TAMPA, Fla.--(BUSINESS WIRE)--Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) today announced that the Company has filed its Quarterly Report (Form 10-Q) with the SEC, reporting the results of its operations, including consolidated results with its majority-owned subsidiary, Biovest International, Inc. (OTCBB:BVTI), for its first fiscal quarter ended December 31, 2007. The Company also provided an update on its anticipated timetable to unblind and publicly-release results on the primary end-point for its Fast Track pivotal Phase 3 clinical trial for SinuNase™, intending to unveil the data on or before March 24, 2008. The Company is scheduled to present at the BioCentury “Future Leaders in the Biotech Industry” Conference on March 27th in New York City. In other news related to the Company’s strategic focus on Ear, Nose and Throat (ENT) products, Accentia announced that is has entered into an agreement with Arbor Pharmaceuticals, Inc., granting Accentia U.S. commercial marketing rights to Neotic™, a novel, patented, prescription solution indicated for acute middle ear infections (acute otitis media).
